Olverembatinib (HQP-1351)
Jump to navigation
Jump to search
Mechanism of action
Third-generation TKI
Diseases for which it is used
History of changes in NMPA indication
- 2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant CML-CP or CML-AP harboring the T315I mutation as confirmed by a validated diagnostic test. (Based on HQP1351CC203)
Also known as
- Code name: HQP-1351